Current advances in the translation of vascular tissue engineering to the treatment of pediatric congenital heart disease.
Tissue-engineered vascular grafts (TEVGs) hold great promise for the improvement of outcomes in pediatric patients with congenital cardiac anomalies. Currently used synthetic grafts have several limitations, including thrombogenicity, increased risk of infection, and lack of growth potential. The first pilot clinical trial of TEVGs demonstrated the feasibility of this new technology and revealed an excellent safety profile. However, long-term follow-up from this trial revealed the primary graft-related complication to be stenosis, affecting 16 percent of grafts within 7 years post-implantation. In order to determine the mechanism behind TEVG stenosis and ultimately to create improved second generation TEVGs, our group has returned to the bench to study vascular neotissue formation in a variety of large and small animal models. The purpose of this report is to review the recent advances in the understanding of neotissue formation and vascular tissue engineering.
Interdepartmental Program in Vascular Biology and Therapeutics, Yale School of Medicine, New Haven, CT 06520, USA.
Ethan W
EW
Dean
Brooks
B
Udelsman
Christopher K
CK
Breuer
D000818:Animals; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000379:methods / Q000639:trends; D002648:Child; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D023421:Models, Animal; D023822:Tissue Engineering / Q000379:methods* / Q000639:trends; D054457:Tissue Scaffolds; D057170:Translational Research, Biomedical / Q000379:methods* / Q000639:trends